Products SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo
SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo Phase 1 Completed 💤 Quiet Mar 22, 2021 → Nov 10, 2021
About SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for HIV-1 Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT04802811. Target conditions include HIV-1 Infection.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT04802811 Phase 1 Completed Mar 22, 2021 Nov 10, 2021 HIV-1 Infection
Product Company Stage Hype Score DOR/ISL Merck Phase 2 Darunavir + Etravirine + Emtricitabine/tenofovir disoproxil fumarate + Raltegravir + Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs) + Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available AbbVie Approved lopinavir/ritonavir + lamivudine AbbVie Pre-clinical CVC 150 mg + CVC 300 mg AbbVie Phase 2 Doravirine, Tenofovir, Lamivudine - Blinded + Doravirine, Tenofovir, Lamivudine - Open-Label + ATRIPLA^TM + Placebo to ATRIPLA™ + Placebo to Doravirine, Tenofovir, Lamivudine Merck Phase 2 DOR/ISL + BIC/FTC/TAF + Placebo to BIC/FTC/TAF + Placebo to DOR/ISL Merck Phase 3 Vorinostat Merck Phase 1/2 Islatravir Merck Phase 1 Doravirine, Tenofovir, Lamivudine + Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor + Baseline regimen of cobicistat-boosted elvitegravir + Baseline regimen of a non-nucleoside reverse transcriptase inhibitor + Baseline regimen of two nucleoside reverse transcriptase inhibitors Merck Phase 3 raltegravir and etravirine Merck Phase 2 Treatment A: Doravirine 100 mg film coated tablet + Treatment B: Doravirine 150 mg tablet (40% drug loaded granule) + Treatment C: Doravirine 150 mg tablet (30% drug loaded granule) + Treatment D: Doravirine 150 mg tablet (50% drug loaded granule) + Treatment E: Doravirine 100 mg tablet (30% drug loaded granule) Merck Phase 1 ISL + ULO + BIC/FTC/TAF Merck Phase 2 Ulonivirine Merck Phase 1 Islatravir + Placebo to Islatravir + Doravirine + Placebo to Doravirine + Lamivudine + Placebo to Lamivudine + Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate + Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate + Doravirine/Islatravir Merck Phase 2 MK0518 (Raltegravir) + famotidine + omeprazole Merck Phase 1 Doravirine Merck Phase 1 MK-8510 Merck Phase 1 18F-Raltegravir Merck Phase 1 Pegylated Interferon alpha 2b Merck Phase 2 MK-8583 Merck Phase 1
Other Products from Jiangsu Hengrui Medicine